3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
1
Lung Neoplasms
1
Esophageal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma
1
Interventions
Fluorouracil
34
Cisplatin
34
Radiotherapy
30
Oxaliplatin
30
Paclitaxel
22
pembrolizumab
20
Irinotecan
20
Docetaxel
20
Leucovorin
19
Capecitabine
16
Cetuximab
11
Carboplatin
11
Bevacizumab
11
Radiation
10
Surgical Procedures, Operative
9
Trastuzumab
8
Panitumumab
6
Epirubicin
6
Neoadjuvant Therapy
5
Esophagectomy
4
Erlotinib Hydrochloride
4
Chemotherapy, Adjuvant
4
tisotumab vedotin
3
durvalumab
3
Sunitinib
3
Microarray Analysis
3
Immunohistochemistry
3
Gene Expression Profiling
3
Gemcitabine
3
Albumin-Bound Paclitaxel
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Esophageal Neoplasms
×
matuzumab
×
Clear all
NCT00215644
2018-11-02
MATRIX EG
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
72 enrolled
7 charts